Epoch Investment Partners Inc. cut its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 52.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 394,329 shares of the medical instruments supplier’s stock after selling 439,664 shares during the period. Epoch Investment Partners Inc. owned about 2.01% of LeMaitre Vascular worth $9,322,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Texas Permanent School Fund grew its stake in shares of LeMaitre Vascular by 4.6% in the fourth quarter. Texas Permanent School Fund now owns 10,380 shares of the medical instruments supplier’s stock valued at $245,000 after buying an additional 461 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of LeMaitre Vascular by 2.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 20,726 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 480 shares in the last quarter. Bank of Montreal Can grew its stake in shares of LeMaitre Vascular by 99.1% in the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 554 shares in the last quarter. Albion Financial Group UT grew its stake in shares of LeMaitre Vascular by 6.5% in the third quarter. Albion Financial Group UT now owns 9,259 shares of the medical instruments supplier’s stock valued at $359,000 after buying an additional 569 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of LeMaitre Vascular by 151.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,513 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 912 shares in the last quarter. Institutional investors own 76.71% of the company’s stock.

LMAT has been the subject of several analyst reports. BidaskClub cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 7th. Zacks Investment Research cut shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Thursday, December 6th. ValuEngine raised shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. Lake Street Capital reissued a “hold” rating and issued a $24.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, January 23rd. Finally, Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a research report on Thursday, February 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. LeMaitre Vascular has a consensus rating of “Hold” and a consensus price target of $33.29.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 16,604 shares of LeMaitre Vascular stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $29.63, for a total transaction of $491,976.52. Following the completion of the transaction, the insider now directly owns 19,857 shares of the company’s stock, valued at $588,362.91. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 20.30% of the company’s stock.

LMAT stock opened at $30.42 on Friday. LeMaitre Vascular Inc has a one year low of $21.79 and a one year high of $41.28. The firm has a market cap of $588.62 million, a price-to-earnings ratio of 36.21, a P/E/G ratio of 2.98 and a beta of 1.15.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, February 19th. The medical instruments supplier reported $0.24 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.24. LeMaitre Vascular had a net margin of 21.73% and a return on equity of 17.71%. The firm had revenue of $28.39 million during the quarter, compared to analysts’ expectations of $26.06 million. On average, equities analysts predict that LeMaitre Vascular Inc will post 0.84 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 22nd will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.12%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.07. The ex-dividend date of this dividend is Thursday, March 21st. LeMaitre Vascular’s payout ratio is 33.33%.

COPYRIGHT VIOLATION NOTICE: “Epoch Investment Partners Inc. Sells 439,664 Shares of LeMaitre Vascular Inc (LMAT)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://theolympiareport.com/2019/03/15/epoch-investment-partners-inc-sells-439664-shares-of-lemaitre-vascular-inc-lmat.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: Bear Market – How and Why They Occur

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.